MXPA04000340A - FORMULACION LIQUIDA QUE COMPRENDE CETUXIMAB Y eSTER DE aCIDO GRASO DE POLIOXIETILEN SORBITaN. - Google Patents

FORMULACION LIQUIDA QUE COMPRENDE CETUXIMAB Y eSTER DE aCIDO GRASO DE POLIOXIETILEN SORBITaN.

Info

Publication number
MXPA04000340A
MXPA04000340A MXPA04000340A MXPA04000340A MXPA04000340A MX PA04000340 A MXPA04000340 A MX PA04000340A MX PA04000340 A MXPA04000340 A MX PA04000340A MX PA04000340 A MXPA04000340 A MX PA04000340A MX PA04000340 A MXPA04000340 A MX PA04000340A
Authority
MX
Mexico
Prior art keywords
cetuximab
fatty acid
acid ester
polyoxyethylene sorbitan
liquid formulation
Prior art date
Application number
MXPA04000340A
Other languages
English (en)
Inventor
Mahler Hanns-Christian
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA04000340A publication Critical patent/MXPA04000340A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

La invencion se relaciona con una formulacion farmaceutica liquida estable que comprende Cetuximab(r), un anticuerpo monoclonal quimerico contra el receptor del factor de crecimiento endotelial (receptor EGF). La formulacion tiene una mayor estabilidad de almacenamiento y puede usarse por via parenteral para el tratamiento de tumores.
MXPA04000340A 2001-07-13 2002-06-18 FORMULACION LIQUIDA QUE COMPRENDE CETUXIMAB Y eSTER DE aCIDO GRASO DE POLIOXIETILEN SORBITaN. MXPA04000340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10133394A DE10133394A1 (de) 2001-07-13 2001-07-13 Flüssige Formulierung enthaltend Cetuximab
PCT/EP2002/006696 WO2003007988A1 (de) 2001-07-13 2002-06-18 Flüssige formulierung enthaltend cetuximab und einen polyoxyethylensorbitanfettsäureester

Publications (1)

Publication Number Publication Date
MXPA04000340A true MXPA04000340A (es) 2004-05-04

Family

ID=7691220

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000340A MXPA04000340A (es) 2001-07-13 2002-06-18 FORMULACION LIQUIDA QUE COMPRENDE CETUXIMAB Y eSTER DE aCIDO GRASO DE POLIOXIETILEN SORBITaN.

Country Status (18)

Country Link
US (1) US20040170632A1 (es)
EP (1) EP1406658A1 (es)
JP (1) JP2004536129A (es)
KR (1) KR20040018458A (es)
CN (1) CN1231264C (es)
AR (1) AR039358A1 (es)
BR (1) BR0211060A (es)
CA (1) CA2453342A1 (es)
CZ (1) CZ2004189A3 (es)
DE (1) DE10133394A1 (es)
HU (1) HUP0401046A3 (es)
MX (1) MXPA04000340A (es)
PE (1) PE20030433A1 (es)
PL (1) PL364599A1 (es)
RU (1) RU2004102395A (es)
SK (1) SK862004A3 (es)
WO (1) WO2003007988A1 (es)
ZA (1) ZA200401161B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3417875T3 (da) * 2003-02-10 2020-08-31 Biogen Ma Inc Immunglobulinformulering og fremgangsmåde til fremstilling deraf
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
AU2005211890B2 (en) * 2004-02-12 2011-07-28 Merck Patent Gmbh Highly concentrated liquid formulations of anti-EGFR antibodies
MXPA06012145A (es) * 2004-04-27 2007-01-31 Wellstat Biologics Corp Tratamiento del cancer utilizando virus y camptotecinas.
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
CN101163468A (zh) * 2005-02-28 2008-04-16 卫材R&D管理有限公司 磺酰胺化合物的新联合用途
NZ570381A (en) 2006-02-09 2011-02-25 Daiichi Sankyo Co Ltd Anti-cancer pharmaceutical composition
WO2007128557A1 (en) 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
AU2007307107B2 (en) * 2006-10-06 2011-11-03 Amgen Inc. Stable antibody formulations
TW200833357A (en) * 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
CN107773755B (zh) * 2016-08-31 2021-06-22 上海津曼特生物科技有限公司 抗表皮生长因子受体单克隆抗体的注射液制剂
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
KR20210024082A (ko) 2018-06-25 2021-03-04 제이씨알 파마 가부시키가이샤 단백질 함유 수성 액제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
JPH11507535A (ja) * 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
PT1516628E (pt) * 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável

Also Published As

Publication number Publication date
HUP0401046A2 (en) 2006-04-28
BR0211060A (pt) 2004-07-20
AR039358A1 (es) 2005-02-16
KR20040018458A (ko) 2004-03-03
HUP0401046A3 (en) 2006-11-28
DE10133394A1 (de) 2003-01-30
CA2453342A1 (en) 2003-01-30
EP1406658A1 (de) 2004-04-14
SK862004A3 (en) 2004-07-07
PL364599A1 (en) 2004-12-13
ZA200401161B (en) 2004-10-22
US20040170632A1 (en) 2004-09-02
WO2003007988A1 (de) 2003-01-30
CN1527724A (zh) 2004-09-08
JP2004536129A (ja) 2004-12-02
CZ2004189A3 (cs) 2004-05-12
PE20030433A1 (es) 2003-05-24
RU2004102395A (ru) 2005-05-27
CN1231264C (zh) 2005-12-14

Similar Documents

Publication Publication Date Title
MXPA04000340A (es) FORMULACION LIQUIDA QUE COMPRENDE CETUXIMAB Y eSTER DE aCIDO GRASO DE POLIOXIETILEN SORBITaN.
MY139055A (en) Lyophilised preparation containing antibodies to the egf receptor
IL178474A0 (en) Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same
PT1412384E (pt) Formulação estável de glp-1 modificado
AU2001231763A1 (en) Dosing regimen
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
AU2000233235A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
JO3449B1 (ar) صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
JO3000B1 (ar) مركبات أجسام مضادة .
IL214325A (en) Antibody against cmet, a drug that includes and uses it
MY129150A (en) Novel sulfamides
MXPA02010648A (es) Formulaciones liquidas.
TW200736277A (en) RANKL antibody-PTH/PTHrP chimeric molecules
AU2002359727A1 (en) Fused cyclic modulators of nuclear hormone receptor function
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
EP1755388A4 (en) MIXED CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
AU2003205768A1 (en) Methods and compositions for treating hyperproliferative conditions
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
AU2001234273A1 (en) Thiazolopyrimidines and their use as modulators of chemokine receptor activity
AP1696A (en) Agrochemical formulations comprising ALS inhibitors.
MXPA03011059A (es) Procedimiento para dosificar un combustible con un aditivo de combustible.